Standard BioTools Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Standard BioTools Inc. (LAB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.05M, a 36.59% decline year-over-year.
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.82M, a 2.05% decline year-over-year.
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.47M, a 43.12% increase year-over-year.
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.39M, a 5.10% decline year-over-year.
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $29.61M, a 6.68% decline from fiscal 2024.
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $31.73M, a 141.80% increase from fiscal 2023.
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $13.12M, a 11.81% decline from fiscal 2022.
- Standard BioTools Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $14.88M, a 7.58% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.05M 10-Q · filed 2026-08-05 | $12.87M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $8.82M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $29.61M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $8.47M 10-Q · filed 2025-11-04 | $14.86M derived: sum of 2 quarters · filed 2026-08-05 | $23.87M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $6.39M 10-Q · filed 2026-08-05 | $15.40M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $9.01M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $31.73M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $5.92M 10-Q · filed 2025-11-04 | $12.65M derived: sum of 2 quarters · filed 2025-11-04 | $24.26M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $6.73M 10-Q · filed 2025-11-04 | $18.34M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $11.61M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $13.12M 10-K · filed 2026-03-16 | |||
| 2023-09-30 | $3.39M 10-Q · filed 2024-11-06 | $6.50M derived: sum of 2 quarters · filed 2024-11-06 | $9.65M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $3.11M 10-Q · filed 2024-11-06 | $6.26M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $3.15M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $14.88M 10-K · filed 2025-03-11 | |||
| 2022-09-30 | $4.49M 10-Q · filed 2023-11-07 | $9.16M derived: sum of 2 quarters · filed 2023-11-07 | $13.20M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $4.66M 10-Q · filed 2023-11-07 | $8.71M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $4.04M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $16.10M 10-K · filed 2023-03-14 | |||
| 2021-09-30 | $4.32M 10-Q · filed 2022-11-09 | $8.06M derived: sum of 2 quarters · filed 2022-11-09 | $11.74M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $3.74M 10-Q · filed 2022-11-09 | $7.42M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $3.68M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $14.45M 10-K · filed 2022-03-08 | |||
| 2020-09-30 | $4.36M 10-Q · filed 2021-11-09 | $7.99M derived: sum of 2 quarters · filed 2021-11-09 | $10.36M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $3.63M 10-Q · filed 2021-11-09 | $6.00M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $2.36M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $11.35M 10-K · filed 2022-03-08 | |||
| 2019-09-30 | $3.06M 10-Q · filed 2020-11-09 | $6.04M derived: sum of 2 quarters · filed 2020-11-09 | $8.25M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $2.98M 10-Q · filed 2020-11-09 | $5.19M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $2.21M 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $11.02M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $2.30M 10-Q · filed 2019-11-08 | $4.31M derived: sum of 2 quarters · filed 2019-11-08 | $6.06M derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $2.01M 10-Q · filed 2019-11-08 | $3.75M derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | $1.75M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $9.09M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $13.86M 10-K · filed 2019-03-18 | |||
| 2015-12-31 | $16.83M 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $20.94M 10-K · filed 2017-03-03 | |||
| 2013-12-31 | $6.44M 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $4.09M 10-K · filed 2015-02-26 | |||
| 2011-12-31 | $2.80M 10-K · filed 2014-03-12 | |||
| 2010-12-31 | $1.59M 10-K · filed 2013-03-12 | |||
| 2009-12-31 | $2.11M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |